Sign in
TerminatedPhase 3

Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Memphis, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 3
People taking part
15 people enrolled
Started
29 Jan 2021
Ended
16 Jan 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tranexamic Acid
  • 0.9% sodium chloride
Record updated
20 December 2024
Why it stopped
Per sponsor

Who can take part

Age
Up to 24 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Participant undergoing limb salvage procedure of malignant bone tumor of the distal femur or proximal tibia, which typically requires blood transfusions
  • Patient under the age of 25
  • Adequate bone marrow function defined as:; Upward trending peripheral absolute neutrophil count (ANC); Platelet count ≥ 100,000/mm\^3 (transfusion independent defined as no platelets required for 4 days); Hemoglobin ≥ 8.0 g/dL; No RBC transfusion within 24 hours
  • Adequate renal function defined as:; Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73m\^2 OR; Maximum serum creatinine based on age/gender as follows: Age 1 day to < 1 years: maximum serum creatinine (mg/dL) 0.6 for males and 0.5 for females; Age 1 to < 2 years: maximum serum creatinine (mg/dL) 0.6 for males and 0.6 for females; Age 2 to < 6 years: maximum serum creatinine (mg/dL) 0.8 for males and 0.8 for females; Age 6 to < 10 years: maximum serum creatinine (mg/dL) 1.0 for males and 1.0 for females; Age 10 to < 13 years: maximum serum creatinine (mg/dL) 1.2 for males and 1.2 for females; Age 13 to < 16 years: maximum serum creatinine (mg/dL) 1.5 for males and 1.4 for females; Age ≥ 16 years: maximum serum creatinine (mg/dL) 1.7 for males and 1.4 for females
  • Adequate liver function defined as:; Total bilirubin ≤ 1.5x the institutional upper limit of normal (IULN) for age; ALT (SGPT) and AST (SGOT) ≤ 2.5x IULN for age (or <5x IULN for patients with documented disease involving the liver or 10x IULN for patients receiving HDMTX); Serum albumin > 2 g/dL
  • Adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5
  • Female participants of child-bearing potential (>10 years old) must have a negative serum or urine pregnancy test within 72 hours of sedation

Who cannot take part

  • Participants receiving erythropoietin-stimulating agents (e.g. epoetin alfa)
  • Participants actively receiving all-trans retinoic acid (ATRA) or isotretinoin (Accutane)
  • Participants currently on anticoagulation medications (e.g. warfarin, enoxaparin)
  • Persisting toxicity related to other systemic therapies (e.g. chemotherapy) which constitutes an unacceptable safety risk based on the judgment of the PI and/or the primary treating physician
  • Female participants who are currently receiving estrogen-based contraception therapy
  • Participants enrolled in another clinical trial utilizing an IND/IDE experimental therapy
  • Participants with known allergies to antifibrinolytics
  • Personal history of a thrombosis or active thrombus
  • Participants with a history of seizures. Patients with a history of febrile seizure are eligible
  • Participants with a history of CNS disease
  • Participants with known bleeding disorder
  • Participants with known platelet dysfunction
  • Participants whose limb salvage procedure may require significant manipulation of major blood vessels
  • Participants with known bone marrow deficiency resulting in red blood cell deficiency (e.g. Diamond-Blackfan anemia)
  • Participants with active hemorrhagic cystitis (e.g. alkylator-induced) with gross hematuria or >50 RBCs per high powered field on urinalysis
  • Participants with known hypercoagulopathies
  • Female participants who are currently pregnant or actively breastfeeding
  • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent

Where in United States

  • St. Jude Children's Research HospitalMemphis, United States

About the trial

What the trial wants to find out

This is a randomized double-blind control trial evaluating the use Tranexamic acid (TXA) to decrease blood loss and transfusion requirements in pediatric and young adult cancer patients undergoing a limb salvage procedure that frequently requires perioperative or post-operative transfusions of blood products.

Read full original descriptionShow less

Primary Objective

* To evaluate the difference in intra-or post-operatively transfused blood volume (mL/kg) for patients undergoing limb salvage procedures of the distal femur or proximal tibia who are randomized to receive perioperative tranexamic acid (TXA) versus placebo.

Secondary Objectives

* To evaluate changes in platelets and in hemoglobin from pre-op to post-op level for patients randomized to receive perioperative TXA versus placebo. * To evaluate differences in post-operative daily surgical drain output for patients randomized to receive perioperative TXA versus placebo. * To evaluate changes in estimated blood loss (EBL) for patients randomized to receive perioperative TXA versus placebo. * To evaluate the association between the intra-or post-operatively transfused blood volume and estimated blood loss (EBL) for patients randomized to receive perioperative TXA and placebo, respectively.

Exploratory Objectives

* To evaluate differences in functional outcomes post-operatively for patients randomized to receive perioperative TXA versus placebo. * To explore if significant correlations are observed between parameters reported with rotational thromboelastometry (ROTEM®) and EBL and transfusion requirements in pediatric and young adult patients undergoing limb salvage procedure who are randomized to perioperative TXA versus placebo. * To evaluate differences in the prevalence and management of wound complications such as superficial or periprosthetic infections, wound dehiscence, contact dermatitis, post- operative hematomas, or any other clinically significant wound complication between patients randomized to receive perioperative TXA versus placebo.

The 2 groups in the trial

  • Tranexamic AcidTreatment being tested

    At initiation of surgical preparation, participants randomized to the active treatment arm will receive tranexamic acid 10 mg/kg (max 1 g), given via syringe pump programmed to infuse over 15 minutes. If no unacceptable toxicities occur, a second dose of tranexamic acid IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).

  • PlaceboPlacebo, for comparison

    At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).

    Treatment: 0.9% sodium chloride

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tranexamic Acid (TXA) to Reduce Volume Of Blood Transfused In Pediatric And Young Adult Cancer Patients Undergoing Limb Salvage Procedure Of A Lower Extremity
Record updated
20 December 2024